Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Stroke

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 68 articles:
HTML format
Text format



Single Articles


    May 2019
  1. PUYMIRAT E, Cayla G, Cottin Y, Elbaz M, et al
    Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015.
    Am Heart J. 2019;214:97-106.
    PubMed     Text format     Abstract available


    January 2019
  2. MACHLINE-CARRION MJ, Santucci EV, Damiani LP, Bahit C, et al
    An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial.
    Am Heart J. 2019;207:49-57.
    PubMed     Text format     Abstract available


  3. GONG E, Gu W, Sun C, Turner EL, et al
    System-integrated technology-enabled model of care to improve the health of stroke patients in rural China: protocol for SINEMA-a cluster-randomized controlled trial.
    Am Heart J. 2019;207:27-39.
    PubMed     Text format     Abstract available


    November 2018
  4. ALEXANDER KP, Brouwer MA, Mulder H, Vinereanu D, et al
    Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial.
    Am Heart J. 2018 Nov 22. pii: S0002-8703(18)30296.
    PubMed     Text format     Abstract available


  5. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    PubMed     Text format     Abstract available


    October 2018
  6. DAVISON WJ, Myint PK, Clark AB, Potter JF, et al
    Blood pressure differences between home monitoring and daytime ambulatory values and their reproducibility in treated hypertensive stroke and TIA patients.
    Am Heart J. 2018;207:58-65.
    PubMed     Text format     Abstract available


  7. BEINART SC, Natale A, Verma A, Amin A, et al
    Real-world comparison of in-hospital Reveal LINQ insertable cardiac monitor insertion inside and outside of the cardiac catheterization or electrophysiology laboratory.
    Am Heart J. 2018 Oct 14. pii: S0002-8703(18)30295.
    PubMed     Text format     Abstract available


    July 2018
  8. PASSMAN R
    Atrial fibrillation and stroke: The more we learn, the less we understand.
    Am Heart J. 2018;201:158-159.
    PubMed     Text format    


    June 2018
  9. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    PubMed     Text format     Abstract available


  10. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Am Heart J. 2018;200:83-89.
    PubMed     Text format     Abstract available


  11. LUBITZ SA, Khurshid S, Weng LC, Doros G, et al
    Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk.
    Am Heart J. 2018;200:24-31.
    PubMed     Text format     Abstract available


  12. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    PubMed     Text format     Abstract available


  13. CHEN ST, Hellkamp AS, Becker RC, Berkowitz SD, et al
    Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF.
    Am Heart J. 2018;200:102-109.
    PubMed     Text format     Abstract available


    May 2018
  14. YAO X, Gersh BJ, Sangaralingham LR, Shah ND, et al
    Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
    Am Heart J. 2018;199:137-143.
    PubMed     Text format     Abstract available


    April 2018
  15. HUISMAN MV, Rothman KJ, Paquette M, Teutsch C, et al
    Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
    Am Heart J. 2018;198:55-63.
    PubMed     Text format     Abstract available


  16. HIJAZI Z, Hohnloser SH, Oldgren J, Andersson U, et al
    Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis.
    Am Heart J. 2018;198:169-177.
    PubMed     Text format    


  17. MIYAZAWA K, Pastori D, Lip GYH
    Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants.
    Am Heart J. 2018;198:166-168.
    PubMed     Text format    


    March 2018
  18. LOOP MS, McClure LA, Levitan EB, Al-Hamdan MZ, et al
    Fine particulate matter and incident coronary heart disease in the REGARDS cohort.
    Am Heart J. 2018;197:94-102.
    PubMed     Text format     Abstract available


  19. RIVERA-CARAVACA JM, Roldan V, Esteve-Pastor MA, Valdes M, et al
    Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED.
    Am Heart J. 2018;197:27-34.
    PubMed     Text format     Abstract available


  20. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    PubMed     Text format     Abstract available


  21. VERMA A, Ha ACT, Kirchhof P, Hindricks G, et al
    The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
    Am Heart J. 2018;197:124-132.
    PubMed     Text format     Abstract available


  22. FANNING JP, Wesley AJ, Walters DL, Wong AA, et al
    Topographical distribution of perioperative cerebral infarction associated with transcatheter aortic valve implantation.
    Am Heart J. 2018;197:113-123.
    PubMed     Text format     Abstract available


  23. HWANG D, Park KW, Lee JM, Rhee TM, et al
    Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease.
    Am Heart J. 2018;197:103-112.
    PubMed     Text format     Abstract available


  24. SHERWOOD MW, Lopes RD, Sun JL, Liaw D, et al
    Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
    Am Heart J. 2018;197:1-8.
    PubMed     Text format     Abstract available


    January 2018
  25. YONG CM, Liu Y, Apruzzese P, Doros G, et al
    Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry.
    Am Heart J. 2018;195:50-59.
    PubMed     Text format     Abstract available


  26. CLARK NP, Douketis JD, Hasselblad V, Schulman S, et al
    Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial.
    Am Heart J. 2018;195:108-114.
    PubMed     Text format     Abstract available


    December 2017
  27. OKUMURA K, Lip GYH, Akao M, Tanizawa K, et al
    Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
    Am Heart J. 2017;194:99-106.
    PubMed     Text format     Abstract available


  28. STEINBERG BA, Gao H, Shrader P, Pieper K, et al
    International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
    Am Heart J. 2017;194:132-140.
    PubMed     Text format     Abstract available


    November 2017
  29. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
    Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
    Am Heart J. 2017;193:46-54.
    PubMed     Text format     Abstract available


    October 2017
  30. MOJOLI M, Gersh BJ, Barioli A, Masiero G, et al
    Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis.
    Am Heart J. 2017;192:64-75.
    PubMed     Text format     Abstract available


  31. VINEREANU D, Al-Khalidi HR, Rao MP, He W, et al
    Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF
    Am Heart J. 2017;192:38-47.
    PubMed     Text format     Abstract available


  32. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    PubMed     Text format     Abstract available


    September 2017
  33. O'NEILL ES, Grande SW, Sherman A, Elwyn G, et al
    Availability of patient decision aids for stroke prevention in atrial fibrillation: A systematic review.
    Am Heart J. 2017;191:1-11.
    PubMed     Text format     Abstract available


    August 2017
  34. HIJAZI Z, Oldgren J, Andersson U, Connolly SJ, et al
    Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Am Heart J. 2017;190:94-103.
    PubMed     Text format     Abstract available


  35. BERNSTEIN RA, Kamel H, Granger CB, Kowal RC, et al
    Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale.
    Am Heart J. 2017;190:19-24.
    PubMed     Text format     Abstract available


  36. KIRCHHOF P, Blank BF, Calvert M, Camm AJ, et al
    Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Am Heart J. 2017;190:12-18.
    PubMed     Text format     Abstract available


    July 2017
  37. HOLMES DR, Reddy VY, Buchbinder M, Stein K, et al
    The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial.
    Am Heart J. 2017;189:68-74.
    PubMed     Text format     Abstract available


  38. STEINBERG BA, Shrader P, Thomas L, Ansell J, et al
    Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2017;189:40-47.
    PubMed     Text format     Abstract available


    June 2017
  39. NEAL B, Tian M, Li N, Elliott P, et al
    Rationale, design, and baseline characteristics of the Salt Substitute and Stroke Study (SSaSS)-A large-scale cluster randomized controlled trial.
    Am Heart J. 2017;188:109-117.
    PubMed     Text format     Abstract available


    May 2017
  40. KARLSSON LO, Nilsson S, Charitakis E, Bang M, et al
    Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting.
    Am Heart J. 2017;187:45-52.
    PubMed     Text format     Abstract available


  41. HESS CN, Clare RM, Neely ML, Tricoci P, et al
    Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
    Am Heart J. 2017;187:194-203.
    PubMed     Text format     Abstract available


  42. DIEDERICHSEN SZ, Haugan KJ, Kober L, Hojberg S, et al
    Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial.
    Am Heart J. 2017;187:122-132.
    PubMed     Text format     Abstract available


  43. MENTZ RJ, Bethel MA, Gustavson S, Thompson VP, et al
    Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Am Heart J. 2017;187:1-9.
    PubMed     Text format     Abstract available


    April 2017
  44. DUCROCQ G, Schulte PJ, Budaj A, Cornel JH, et al
    Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    Am Heart J. 2017;186:91-99.
    PubMed     Text format     Abstract available


    March 2017
  45. NAKANISHI K, Jin Z, Homma S, Elkind MS, et al
    Left ventricular mass-geometry and silent cerebrovascular disease: The Cardiovascular Abnormalities and Brain Lesions (CABL) study.
    Am Heart J. 2017;185:85-92.
    PubMed     Text format     Abstract available


  46. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    PubMed     Text format     Abstract available


  47. LEE H, Koo BK, Park KW, Shin ES, et al
    A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary arte
    Am Heart J. 2017;185:17-25.
    PubMed     Text format     Abstract available


  48. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
    Acute coronary syndrome quality improvement in Kerala (ACS QUIK): Rationale and design for a cluster-randomized stepped-wedge trial.
    Am Heart J. 2017;185:154-160.
    PubMed     Text format     Abstract available


  49. WESTENBRINK BD, Alings M, Granger CB, Alexander JH, et al
    Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Am Heart J. 2017;185:140-149.
    PubMed     Text format     Abstract available


    February 2017
  50. ARMSTRONG PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, et al
    Corrigendum to "Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial" [Am Heart J 169/6 (2015) 890-898].
    Am Heart J. 2017;184:157.
    PubMed     Text format    


  51. FANOLA CL, Mooney D, Cowan AJ, Ko D, et al
    Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants.
    Am Heart J. 2017;184:150-155.
    PubMed     Text format     Abstract available


  52. BERWANGER O, de Barros E Silva PG, Barbosa RR, Precoma DB, et al
    Atorvastatin for high-risk statin-naive patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.
    Am Heart J. 2017;184:88-96.
    PubMed     Text format     Abstract available


  53. KHAN H, Jaffar N, Rauramaa R, Kurl S, et al
    Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study.
    Am Heart J. 2017;184:55-61.
    PubMed     Text format     Abstract available


    January 2017
  54. OSMANCIK P, Tousek P, Herman D, Neuzil P, et al
    Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study).
    Am Heart J. 2017;183:108-114.
    PubMed     Text format     Abstract available


    November 2016
  55. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    PubMed     Text format     Abstract available


  56. STEINBERG BA, Shrader P, Kim S, Thomas L, et al
    How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Am Heart J. 2016;181:145-152.
    PubMed     Text format     Abstract available


  57. VALENTINO M, Al Danaf J, Panakos A, Ragupathi L, et al
    Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
    Am Heart J. 2016;181:130-136.
    PubMed     Text format     Abstract available


  58. FERRI LA, Morici N, Grosseto D, Tortorella G, et al
    A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Am Heart J. 2016;181:101-106.
    PubMed     Text format     Abstract available


    October 2016
  59. WINDECKER S, Tijssen J, Giustino G, Guimaraes AH, et al
    Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Am Heart J. 2016;184:81-87.
    PubMed     Text format     Abstract available


  60. ALLEN JE, Knight S, McCubrey RO, Bair T, et al
    beta-blocker dosage and outcomes after acute coronary syndrome.
    Am Heart J. 2016;184:26-36.
    PubMed     Text format     Abstract available


  61. VAN DER MEERSCH H, De Bacquer D, De Vriese AS
    Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
    Am Heart J. 2016;184:37-46.
    PubMed     Text format     Abstract available


    September 2016
  62. BUCK J, Kaboli P, Gage BF, Cram P, et al
    Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
    Am Heart J. 2016;179:186-91.
    PubMed     Text format     Abstract available


  63. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Am Heart J. 2016;179:175-83.
    PubMed     Text format     Abstract available


  64. TROXEL AB, Asch DA, Mehta SJ, Norton L, et al
    Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program.
    Am Heart J. 2016;179:166-74.
    PubMed     Text format     Abstract available


  65. SHAH R, Hellkamp A, Lokhnygina Y, Becker RC, et al
    Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Am Heart J. 2016;179:77-86.
    PubMed     Text format     Abstract available


  66. DE WAHA A, Sandner S, von Scheidt M, Boening A, et al
    A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Inve
    Am Heart J. 2016;179:69-76.
    PubMed     Text format     Abstract available


  67. EZEKOWITZ MD, Pollack CV, Sanders P, Halperin JL, et al
    Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.
    Am Heart J. 2016;179:59-68.
    PubMed     Text format     Abstract available


    May 2016
  68. GOODMAN SG
    Prior bleeding, future bleeding and stroke risk with oral anticoagulation in atrial fibrillation: What new lessons can ARISTOTLE teach us?
    Am Heart J. 2016;175:168-71.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Stroke is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: